Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Potassium Nitrate→

Potassium Nitrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7757-79-1
Molecular formula
KNO3
Molecular weight
101.103 g/mol
Drug class
Dental desensitising agentpotassium salt used in oral-care preparations
Mechanism of action
Potassium ions diffuse through dentinal tubules and reduce excitability of intradental sensory nerves, decreasing the response to hydrodynamic stimuli that trigger dentine hypersensitivity.
Indications / reported uses
  • Active ingredient in desensitising toothpastes and dental preparations for relief of dentine hypersensitivity, commonly at 5% w/w in authorised oral-care products.

Sources: https://pubmed.ncbi.nlm.nih.gov/27296170/ · https://www.ncbi.nlm.nih.gov/mesh/?term=potassium+nitrate+dental · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Potassium Nitrate Environmental Risk Assessment (ERA) (the Potassium Nitrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.